Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.07
CELG's Cash to Debt is ranked lower than
79% of the 831 Companies
in the Global Biotechnology industry.

( Industry Median: 56.93 vs. CELG: 1.07 )
Ranked among companies with meaningful Cash to Debt only.
CELG' s 10-Year Cash to Debt Range
Min: 0.03   Max: No Debt
Current: 1.07

Equity to Asset 0.39
CELG's Equity to Asset is ranked lower than
78% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CELG: 0.39 )
Ranked among companies with meaningful Equity to Asset only.
CELG' s 10-Year Equity to Asset Range
Min: -0.68   Max: 0.92
Current: 0.39

-0.68
0.92
Interest Coverage 14.30
CELG's Interest Coverage is ranked lower than
89% of the 380 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CELG: 14.30 )
Ranked among companies with meaningful Interest Coverage only.
CELG' s 10-Year Interest Coverage Range
Min: 4.47   Max: 428.04
Current: 14.3

4.47
428.04
F-Score: 8
Z-Score: 7.28
M-Score: -2.51
WACC vs ROIC
14.84%
46.73%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 37.60
CELG's Operating margin (%) is ranked higher than
94% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: -76.18 vs. CELG: 37.60 )
Ranked among companies with meaningful Operating margin (%) only.
CELG' s 10-Year Operating margin (%) Range
Min: -2309.09   Max: 32.84
Current: 37.6

-2309.09
32.84
Net-margin (%) 30.41
CELG's Net-margin (%) is ranked higher than
92% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. CELG: 30.41 )
Ranked among companies with meaningful Net-margin (%) only.
CELG' s 10-Year Net-margin (%) Range
Min: -2309.09   Max: 28.88
Current: 30.41

-2309.09
28.88
ROE (%) 42.95
CELG's ROE (%) is ranked higher than
97% of the 755 Companies
in the Global Biotechnology industry.

( Industry Median: -27.55 vs. CELG: 42.95 )
Ranked among companies with meaningful ROE (%) only.
CELG' s 10-Year ROE (%) Range
Min: -425.42   Max: 33.02
Current: 42.95

-425.42
33.02
ROA (%) 15.33
CELG's ROA (%) is ranked higher than
93% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -23.43 vs. CELG: 15.33 )
Ranked among companies with meaningful ROA (%) only.
CELG' s 10-Year ROA (%) Range
Min: -166.78   Max: 15.8
Current: 15.33

-166.78
15.8
ROC (Joel Greenblatt) (%) 247.86
CELG's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. CELG: 247.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CELG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2116.67   Max: 213.62
Current: 247.86

-2116.67
213.62
Revenue Growth (3Y)(%) 20.60
CELG's Revenue Growth (3Y)(%) is ranked higher than
77% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: -0.10 vs. CELG: 20.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CELG' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 166.8
Current: 20.6

0
166.8
EBITDA Growth (3Y)(%) 20.40
CELG's EBITDA Growth (3Y)(%) is ranked higher than
77% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. CELG: 20.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CELG' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 75.6
Current: 20.4

0
75.6
EPS Growth (3Y)(%) 19.00
CELG's EPS Growth (3Y)(%) is ranked higher than
76% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. CELG: 19.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CELG' s 10-Year EPS Growth (3Y)(%) Range
Min: -63.2   Max: 118.1
Current: 19

-63.2
118.1
» CELG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

CELG Guru Trades in Q2 2014

George Soros 688,000 sh (New)
Stanley Druckenmiller 276,000 sh (New)
Joel Greenblatt 63,980 sh (New)
Ken Fisher 131,064 sh (+75.59%)
Mario Gabelli 23,120 sh (+7.34%)
Steven Cohen 204,200 sh (unchged)
Ray Dalio Sold Out
Chuck Royce Sold Out
Paul Tudor Jones Sold Out
John Burbank Sold Out
Louis Moore Bacon Sold Out
Pioneer Investments 3,052,643 sh (-1.66%)
RS Investment Management 75,104 sh (-7.44%)
Jeremy Grantham 50,000 sh (-26.69%)
Ronald Muhlenkamp 144,140 sh (-51.74%)
Jim Simons 495,900 sh (-84.57%)
» More
Q3 2014

CELG Guru Trades in Q3 2014

Louis Moore Bacon 55,000 sh (New)
John Hussman 25,000 sh (New)
Stanley Druckenmiller 560,600 sh (+103.12%)
Ken Fisher 232,137 sh (+77.12%)
RS Investment Management 86,904 sh (+15.71%)
Mario Gabelli 25,760 sh (+11.42%)
Ronald Muhlenkamp 146,940 sh (+1.94%)
Pioneer Investments 3,080,374 sh (unchged)
Joel Greenblatt Sold Out
Jeremy Grantham Sold Out
Steven Cohen Sold Out
George Soros Sold Out
Jim Simons 30,400 sh (-93.87%)
» More
Q4 2014

CELG Guru Trades in Q4 2014

Steven Cohen 110,400 sh (New)
Joel Greenblatt 10,259 sh (New)
Paul Tudor Jones 3,776 sh (New)
Pioneer Investments 3,376,570 sh (+9.62%)
Jim Simons Sold Out
Louis Moore Bacon Sold Out
John Hussman Sold Out
Ken Fisher 227,331 sh (-2.07%)
Mario Gabelli 24,960 sh (-3.11%)
RS Investment Management 76,482 sh (-11.99%)
Stanley Druckenmiller 434,100 sh (-22.57%)
Ronald Muhlenkamp 86,240 sh (-41.31%)
» More
Q1 2015

CELG Guru Trades in Q1 2015

Jim Simons 425,600 sh (New)
Murray Stahl 5,000 sh (New)
Bill Frels 1,776 sh (New)
Lee Ainslie 2,230 sh (New)
Ray Dalio 24,296 sh (New)
Joel Greenblatt 17,987 sh (+75.33%)
RS Investment Management 97,369 sh (+27.31%)
Pioneer Investments 3,475,247 sh (+2.92%)
Ken Fisher 229,918 sh (+1.14%)
Steven Cohen 1,000,200 sh (unchged)
Steven Cohen Sold Out
Mario Gabelli 24,940 sh (-0.08%)
Ronald Muhlenkamp 85,540 sh (-0.81%)
Paul Tudor Jones 3,180 sh (-15.78%)
Stanley Druckenmiller 195,975 sh (-54.85%)
» More
» Details

Insider Trades

Latest Guru Trades with CELG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 38.80
CELG's P/E(ttm) is ranked higher than
51% of the 274 Companies
in the Global Biotechnology industry.

( Industry Median: 40.20 vs. CELG: 38.80 )
Ranked among companies with meaningful P/E(ttm) only.
CELG' s 10-Year P/E(ttm) Range
Min: 17.91   Max: 618.59
Current: 38.8

17.91
618.59
Forward P/E 18.55
CELG's Forward P/E is ranked higher than
58% of the 311 Companies
in the Global Biotechnology industry.

( Industry Median: 21.05 vs. CELG: 18.55 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 39.60
CELG's PE(NRI) is ranked lower than
52% of the 211 Companies
in the Global Biotechnology industry.

( Industry Median: 39.20 vs. CELG: 39.60 )
Ranked among companies with meaningful PE(NRI) only.
CELG' s 10-Year PE(NRI) Range
Min: 17.81   Max: 482.5
Current: 39.6

17.81
482.5
P/B 13.30
CELG's P/B is ranked lower than
90% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. CELG: 13.30 )
Ranked among companies with meaningful P/B only.
CELG' s 10-Year P/B Range
Min: 4.02   Max: 23.45
Current: 13.3

4.02
23.45
P/S 11.90
CELG's P/S is ranked higher than
51% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 12.17 vs. CELG: 11.90 )
Ranked among companies with meaningful P/S only.
CELG' s 10-Year P/S Range
Min: 5.37   Max: 28.35
Current: 11.9

5.37
28.35
PFCF 33.00
CELG's PFCF is ranked higher than
54% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 35.83 vs. CELG: 33.00 )
Ranked among companies with meaningful PFCF only.
CELG' s 10-Year PFCF Range
Min: 14.96   Max: 2925.5
Current: 33

14.96
2925.5
POCF 31.12
CELG's POCF is ranked higher than
51% of the 211 Companies
in the Global Biotechnology industry.

( Industry Median: 31.25 vs. CELG: 31.12 )
Ranked among companies with meaningful POCF only.
CELG' s 10-Year POCF Range
Min: 13.82   Max: 937.83
Current: 31.12

13.82
937.83
EV-to-EBIT 30.36
CELG's EV-to-EBIT is ranked higher than
50% of the 207 Companies
in the Global Biotechnology industry.

( Industry Median: 30.27 vs. CELG: 30.36 )
Ranked among companies with meaningful EV-to-EBIT only.
CELG' s 10-Year EV-to-EBIT Range
Min: -26.2   Max: 306.1
Current: 30.36

-26.2
306.1
PEG 1.71
CELG's PEG is ranked higher than
66% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 2.13 vs. CELG: 1.71 )
Ranked among companies with meaningful PEG only.
CELG' s 10-Year PEG Range
Min: 1.38   Max: 2.92
Current: 1.71

1.38
2.92
Shiller P/E 69.20
CELG's Shiller P/E is ranked lower than
67% of the 162 Companies
in the Global Biotechnology industry.

( Industry Median: 43.00 vs. CELG: 69.20 )
Ranked among companies with meaningful Shiller P/E only.
CELG' s 10-Year Shiller P/E Range
Min: 56.57   Max: 2211
Current: 69.2

56.57
2211
Current Ratio 4.61
CELG's Current Ratio is ranked higher than
52% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. CELG: 4.61 )
Ranked among companies with meaningful Current Ratio only.
CELG' s 10-Year Current Ratio Range
Min: 1.35   Max: 44.53
Current: 4.61

1.35
44.53
Quick Ratio 4.42
CELG's Quick Ratio is ranked higher than
52% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: 4.16 vs. CELG: 4.42 )
Ranked among companies with meaningful Quick Ratio only.
CELG' s 10-Year Quick Ratio Range
Min: 1.13   Max: 44.15
Current: 4.42

1.13
44.15
Days Inventory 336.18
CELG's Days Inventory is ranked lower than
87% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 116.85 vs. CELG: 336.18 )
Ranked among companies with meaningful Days Inventory only.
CELG' s 10-Year Days Inventory Range
Min: 49.98   Max: 584
Current: 336.18

49.98
584
Days Sales Outstanding 53.67
CELG's Days Sales Outstanding is ranked higher than
58% of the 557 Companies
in the Global Biotechnology industry.

( Industry Median: 61.96 vs. CELG: 53.67 )
Ranked among companies with meaningful Days Sales Outstanding only.
CELG' s 10-Year Days Sales Outstanding Range
Min: 42.33   Max: 464.55
Current: 53.67

42.33
464.55

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 161.10
CELG's Price/Tangible Book is ranked lower than
111% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: 6.50 vs. CELG: 161.10 )
Ranked among companies with meaningful Price/Tangible Book only.
CELG' s 10-Year Price/Tangible Book Range
Min: 6.24   Max: 338.97
Current: 161.1

6.24
338.97
Price/DCF (Projected) 3.00
CELG's Price/DCF (Projected) is ranked higher than
69% of the 255 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. CELG: 3.00 )
Ranked among companies with meaningful Price/DCF (Projected) only.
CELG' s 10-Year Price/DCF (Projected) Range
Min: 1.66   Max: 122.67
Current: 3

1.66
122.67
Price/Median PS Value 1.10
CELG's Price/Median PS Value is ranked higher than
68% of the 784 Companies
in the Global Biotechnology industry.

( Industry Median: 2.00 vs. CELG: 1.10 )
Ranked among companies with meaningful Price/Median PS Value only.
CELG' s 10-Year Price/Median PS Value Range
Min: 0.51   Max: 7.51
Current: 1.1

0.51
7.51
Price/Peter Lynch Fair Value 1.80
CELG's Price/Peter Lynch Fair Value is ranked higher than
62% of the 84 Companies
in the Global Biotechnology industry.

( Industry Median: 2.30 vs. CELG: 1.80 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
CELG' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.36   Max: 5.1
Current: 1.8

0.36
5.1
Price/Graham Number 16.50
CELG's Price/Graham Number is ranked lower than
92% of the 274 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. CELG: 16.50 )
Ranked among companies with meaningful Price/Graham Number only.
CELG' s 10-Year Price/Graham Number Range
Min: 2.89   Max: 25.83
Current: 16.5

2.89
25.83
Earnings Yield (Greenblatt) 3.30
CELG's Earnings Yield (Greenblatt) is ranked higher than
88% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. CELG: 3.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
CELG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 6.6
Current: 3.3

0.3
6.6
Forward Rate of Return (Yacktman) 23.80
CELG's Forward Rate of Return (Yacktman) is ranked higher than
70% of the 86 Companies
in the Global Biotechnology industry.

( Industry Median: 14.93 vs. CELG: 23.80 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) only.
CELG' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.4   Max: 34.8
Current: 23.8

-0.4
34.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CMXHY » details
Traded in other countries:CG3.Germany, CELG.Mexico, CELG.Switzerland,
Celgene Corp is incorporated in Delaware. The Company is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of new therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in new research and development designed to bring new therapies to market and we are involved in research in several scientific areas that may deliver proprietary next-generation therapies, targeting areas including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The Company' commercial stage products include REVLIMID(r), VIDAZA(r), ABRAXANE(r), POMALYST(r)/IMNOVID(r), THALOMID(r) (inclusive of Thalidomide CelgeneTM), ISTODAX(r) and azacitidine for injection (generic version of VIDAZA(r)). The Company faces competition from Amgen, AstraZeneca, Bristol-Myers-Squibb, Eisai, Gilead, Johnson & Johnson, Novartis, Pharmacyclics, Roche/Genentech, Sanofi and Takeda, AbbVie, Amgen, Biogen Idec, Eisai, Johnson & Johnson, Merck, Pfizer and UCB S.A. Regulation by governmental authorities in the United States and other countries is a significant factor in the manufacture and marketing of pharmaceuticals and in its ongoing research and development activities.
» More Articles for CELG

Headlines

Articles On GuruFocus.com
Big Pharma Companies Are Betting On Regenerative Medicine - Should You? May 26 2015 
jee's porfolio May 23 2015 
Celgene’s Earnings Shine While Revenue Misses By An Inch In The First Quarter May 06 2015 
February Pick Of Biotech Stocks Feb 17 2015 
Celleration Acquisition Just the Start of Alliqua’s M&A Strategy Feb 04 2015 
J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Nov 18 2014 
Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Coun Nov 17 2014 
Three Attractively Priced Small Cap Biotech Stocks Nov 05 2014 
Weekly 52-Week Highs Highlight: ALL, SRE, CLX, CELG Oct 05 2014 

More From Other Websites
BMO: Celgene Still A Buy On This 'Important Future Driver' May 28 2015
Celgene Corporation to Webcast at Upcoming Investor Conferences in June May 28 2015
Celgene Corporation to Webcast at Upcoming Investor Conferences in June May 28 2015
Short Sellers Get Even More Ambitious Against Biotech Leaders May 28 2015
Celgene's 3 Most Important Collaborations May 26 2015
A Sell in May Strategy May 26 2015
The Most Loved Biotechs of Big Hedge Funds May 23 2015
A Beautiful Biotech Summer? May 22 2015
Why Do Biotech Stocks Look Attractive? May 21 2015
Jim Cramer Answers Your Twitter Questions on Tesla, Jarden, Williams-Sonoma, Wayfair May 21 2015
Move Over Chip Stocks: Here Are 5 Top Biotechs May 20 2015
Move Aside, Chip Stocks, Biotechs Are Leaders Too May 20 2015
Celgene/Accelreon's Luspatercept Granted Fast Track Status - Analyst Blog May 19 2015
Analysis of Phase II Data for Celgene's Investigational Oral GED-0301 in Patients with Active... May 19 2015
Analysis of Phase II Data for Celgene’s Investigational Oral GED-0301 in Patients with Active... May 19 2015
Celgene, Lannett Lead Boisterous Day For Drugmakers May 18 2015
Celgene's Crohn's Disease Drug Prompts Lingering Questions May 18 2015
FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with... May 18 2015
FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with... May 18 2015
Celgene, Gilead, Netflix, Costco: Jim Cramer's Views May 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK